首页> 外文期刊>Clinica chimica acta: International journal of clinical chemistry and applied molecular biology >Inclusion bodies of recombinant Epstein-Barr virus capsid antigen p18 as potential immobilized antigens in enzyme immunoassays for detection of nasopharyngeal carcinoma
【24h】

Inclusion bodies of recombinant Epstein-Barr virus capsid antigen p18 as potential immobilized antigens in enzyme immunoassays for detection of nasopharyngeal carcinoma

机译:重组爱泼斯坦-巴尔病毒衣壳抗原p18作为检测鼻咽癌的酶联免疫法中潜在的固定抗原的包涵体

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Development of indirect enzyme-linked immunosorbent assays (ELISAs) often utilizes synthetic peptides or recombinant proteins from Escherichia coli as immobilized antigens. Because inclusion bodies (IBs) formed during recombinant protein expression in E. coli are commonly thought as misfolded aggregates, only refolded proteins from IBs are used to develop new or in-house diagnostic assays. However, the promising utilities of IBs as nanomaterials and immobilized enzymes as shown in recent studies have led us to explore the potential use of IBs of recombinant Epstein-Barr virus viral capsid antigen p18 (VCA p18) as immobilized antigens in ELISAs for serologic detection of nasopharyngeal carcinoma (NPC).
机译:背景:间接酶联免疫吸附测定(ELISA)的发展通常利用大肠杆菌的合成肽或重组蛋白作为固定抗原。由于通常将重组蛋白在大肠杆菌中表达过程中形成的包涵体(IBs)视为折叠错误的聚集体,因此仅将来自IBs的折叠蛋白用于开发新的或内部的诊断检测方法。但是,如最近的研究所示,IBs作为纳米材料和固定化酶的前景广阔,已使我们探索了重组爱泼斯坦-巴尔病毒病毒衣壳抗原p18(VCA p18)IBs作为ELISA中固定化抗原在血清学检测中的潜在用途。鼻咽癌(NPC)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号